Abstract 40P
Background
Camptothecins are effective agents that selectively target topoisomerase I and are widely used as payload in ADC. Myelosuppression is the most common toxicity of camptothecins and ADC. Clinical experience suggests ADC toxicities are primarily driven by payload in a target-independent mechanism. Thus, we hypothesized that a “soft drug” design of camptothecin would result in a set of new payloads that possess potent anti-tumor activities and reduced toxicity. ADCs built from such soft topoisomerase inhibitors may exhibit improved safety to overcome these dose-limiting toxicities.
Methods
Camptothecin was structurally modified to maintain potent in vitro cytotoxicity, and meanwhile, minimize its exposure in circulation to reduce toxicity. We next constituted a Her2 ADC (T-PL1), which was composed of Trastuzumab conjugated to new payload PL1 at a DAR ratio of 8, with the same linker as DS-8201 (T-DXd). PL1 and T-PL1 were evaluated in multiple preclinical studies using standard methodology, in comparison with Dxd and DS-8201.
Results
In vitro studies demonstrated that new camptothecin PL1 had comparable cytotoxicity to Dxd across a panel of tumor cell lines. A rat pharmacokinetic study demonstrated that PL1 was quickly cleared from circulation resulting in low systemic exposure. In a 3-week intermittent toxicity study in rat, Dxd treatment at 3 mg/kg resulted in reduction of lymphocyte, neutrophil, platelet, and white blood cell counts. In contrast, PL1 treatment at 10 mg/kg had no effect on these hematological indices. Its ADC T-PL1 possessed comparable anti-tumor activities to DS-8201, moreover, it also exhibited robust tumor suppression in CDX models. Importantly, in a rat toxicity study, DS-8201 treatment at 60 mg/kg caused decreases in lymphocyte and white blood cell counts, while T-PL1 outperformed it and showed no trend of hematological toxicity at the same dosage.
Conclusions
The STOPIN design not only generated a new camptothecin with great potency and reduced hematological toxicity, but also provided a new ADC exhibiting excellent anti-tumor efficacy and improved safety as compared to DS-8201. This unique feature may provide a new approach to widen the ADC therapeutic window. Further preclinical evaluation of STOPIN-based ADC candidates is underway.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Shanghai MicuRx Pharmaceutical Co., Ltd.
Funding
Shanghai MicuRx Pharmaceutical Co., Ltd.
Disclosure
X. Wang, H. Yang, Y. Li, L. Wang, S. Liu: Financial Interests, Personal, Full or part-time Employment: MicuRx.
Resources from the same session
42P - Correlation of circulating tumor cells with cancer stage
Presenter: Ana Paz
Session: Poster session 07
43P - A redesigned cell atlas of colon cancers to better assess their cellular composition
Presenter: Marine Sroussi
Session: Poster session 07
76P - Improving access to whole genome sequencing for patients with cancer of unknown primary using formalin-fixed paraffin embedded tissues and cell-free DNA
Presenter: Richard Tothill
Session: Poster session 07
77P - Whole-exome mutation profiling of cfDNA from over 2000 samples in major cancer indications
Presenter: Eric Jia
Session: Poster session 07
78P - Real-world analysis of actionable gene fusions identified by NGS and correlation with IHC in 422 patients from the community
Presenter: Husain Hatim
Session: Poster session 07
79P - Comprehensive genomic profiling provides patients access to novel matched therapies in a diverse real-world cohort of advanced lung cancer patients
Presenter: Jyoti Patel
Session: Poster session 07
80P - Development of a next-generation sequencing diagnostics recommender tool in the framework of the molecular tumor board Freiburg
Presenter: Ralf Mertes
Session: Poster session 07
81P - FINPROVE: The Finnish national study to facilitate patient access to targeted anti-cancer drugs – Preliminary data after two years of enrollment
Presenter: Katriina Jalkanen
Session: Poster session 07
82P - Clinical and molecular characteristics of gynecologic cancer patients in FINPROVE: The national phase II drug repurposing trial in Finland
Presenter: Anniina Färkkilä
Session: Poster session 07
83P - Circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) in eary high risk breast cancer: The CITUCEL trial update
Presenter: Roberto Borea
Session: Poster session 07